HK Stock Market Move | Wangshan Wangshui - B (02630) debuts on the market with an opening price of 184.69% in the morning session. The company focuses on small molecule drugs in the fields of neurology and reproductive health.

Wangshanwangshui-B (02630) has just been listed. The announcement shows that the price per share is priced at 33.37 Hong Kong dollars, with a total of 17.5978 million shares issued, and 200 shares per lot, with a net proceeds of approximately 527 million Hong Kong dollars. As of the time of drafting, the stock has increased by 184.69% to 95 Hong Kong dollars, with a trading volume of 274 million Hong Kong dollars. Public information shows that Wangshanwangshui was established in 2013 and is a biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing small molecule drugs in the company's strategic focus treatment areas (neurological and mental health and reproductive health). The company has acquired and developed two core products, LV232 and TPN171. LV232 is a receptor modulator for the dual-target serotonin transporter/serotonin 3 (5-HTT/5-HT3) used to treat severe depression. TPN171 is a type 5 phosphodiesterase (PDE5) inhibitor for the treatment of erectile dysfunction (ED). The company also has four candidate drugs in clinical stages and three candidate drugs in preclinical stages.